Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 117 results for embolism

  1. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and diagrams...

  2. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and diagrams...

  3. Dose strategies for people who are obese:- What is the clinical and cost effectiveness of weight-based dose-adjustment strategies of lowmolecular-weight heparin (LMWH) compared with fixed-dose strategies of LMWH for preventing VTE in people who are very obese (BMI over 35) who are admitted to hospital or having day procedures (including surgery and chemotherapy)?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  4. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  5. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  6. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

    NICE guideline
    Last updated
    13 April 2022
    View recommendations

    Sections for NG128

  7. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021

  8. pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)

    NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .

    Medtech innovation briefing
    Published
    11 August 2020

  9. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

    Medtech innovation briefing
    Published
    1 June 2021

  10. Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA171

  11. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  12. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and diagrams...

  13. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    We have moved interventional procedures guidance 524 to become HealthTech guidance 376. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. 500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

    A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.

    News
    Last updated
    27 March 2026

  15. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and diagrams...